APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Coagulation Factors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Coagulation Factors Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchRecombinant Coagulation Factors Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Coagulation Factors Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Recombinant Coagulation Factors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Coagulation Factors Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Coagulation Factors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Recombinant Coagulation Factors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Coagulation Factors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Coagulation Factors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Coagulation Factors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Coagulation Factors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Coagulation Factors market include Novo Nordisk A/S, Pfizer Inc., Bayer AG, Baxter International Inc., Octapharma AG, Kedrion S.P.A., Grifols International SA, CSL Ltd. and Biogen Idec, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Recombinant Coagulation Factors market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Coagulation Factors and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Coagulation Factors revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Recombinant Coagulation Factors market.

Recombinant Coagulation Factors Segment by Company

Novo Nordisk A/S

Pfizer Inc.

Bayer AG

Baxter International Inc.

Octapharma AG

Kedrion S.P.A.

Grifols International SA

CSL Ltd.

Biogen Idec

Recombinant Coagulation Factors Segment by Type

Recombinant Factor VIII

Recombinant Factor IX

Von Willebrand Factor

Recombinant Coagulation Factors Segment by Application

Clinics

Hospitals

Research Organizations

Recombinant Coagulation Factors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Coagulation Factors status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Recombinant Coagulation Factors key companies, revenue, market share, and recent developments.

3. To split the Recombinant Coagulation Factors breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Recombinant Coagulation Factors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Coagulation Factors significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Coagulation Factors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Coagulation Factors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Coagulation Factors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Coagulation Factors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Coagulation Factors industry.

Chapter 3: Detailed analysis of Recombinant Coagulation Factors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Recombinant Coagulation Factors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Recombinant Coagulation Factors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Coagulation Factors Industry Trends Table 2. Recombinant Coagulation Factors Industry Drivers Table 3. Recombinant Coagulation Factors Industry Opportunities and Challenges Table 4. Recombinant Coagulation Factors Industry Restraints Table 5. Global Recombinant Coagulation Factors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Coagulation Factors Revenue Share by Company (2021-2026) Table 7. Global Recombinant Coagulation Factors Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Recombinant Coagulation Factors Key Company Manufacturing Base & Headquarters Table 9. Global Recombinant Coagulation Factors Company, Product Type & Application Table 10. Global Recombinant Coagulation Factors Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Recombinant Coagulation Factors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Recombinant Factor VIII Table 15. Significant Companies of Recombinant Factor IX Table 16. Significant Companies of Von Willebrand Factor Table 17. Global Recombinant Coagulation Factors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Recombinant Coagulation Factors Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Recombinant Coagulation Factors Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Recombinant Coagulation Factors Sales Value Share by Type (2021-2026) Table 21. Global Recombinant Coagulation Factors Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Clinics Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Research Organizations Table 25. Global Recombinant Coagulation Factors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Recombinant Coagulation Factors Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Recombinant Coagulation Factors Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Recombinant Coagulation Factors Sales Value Share by Application (2021-2026) Table 29. Global Recombinant Coagulation Factors Sales Value Share by Application (2027-2032) Table 30. Global Recombinant Coagulation Factors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Recombinant Coagulation Factors Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Recombinant Coagulation Factors Sales Value Share by Region (2021-2026) Table 33. Global Recombinant Coagulation Factors Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Recombinant Coagulation Factors Sales Value Share by Region (2027-2032) Table 35. Global Recombinant Coagulation Factors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Recombinant Coagulation Factors Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Recombinant Coagulation Factors Sales Value Market Share by Country (2021-2026) Table 38. Global Recombinant Coagulation Factors Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Recombinant Coagulation Factors Sales Value Market Share by Country (2027-2032) Table 40. Novo Nordisk A/S Company Information Table 41. Novo Nordisk A/S Business Overview Table 42. Novo Nordisk A/S Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Novo Nordisk A/S Recombinant Coagulation Factors Product Portfolio Table 44. Novo Nordisk A/S Recent Development Table 45. Pfizer Inc. Company Information Table 46. Pfizer Inc. Business Overview Table 47. Pfizer Inc. Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Pfizer Inc. Recombinant Coagulation Factors Product Portfolio Table 49. Pfizer Inc. Recent Development Table 50. Bayer AG Company Information Table 51. Bayer AG Business Overview Table 52. Bayer AG Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Bayer AG Recombinant Coagulation Factors Product Portfolio Table 54. Bayer AG Recent Development Table 55. Baxter International Inc. Company Information Table 56. Baxter International Inc. Business Overview Table 57. Baxter International Inc. Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Baxter International Inc. Recombinant Coagulation Factors Product Portfolio Table 59. Baxter International Inc. Recent Development Table 60. Octapharma AG Company Information Table 61. Octapharma AG Business Overview Table 62. Octapharma AG Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Octapharma AG Recombinant Coagulation Factors Product Portfolio Table 64. Octapharma AG Recent Development Table 65. Kedrion S.P.A. Company Information Table 66. Kedrion S.P.A. Business Overview Table 67. Kedrion S.P.A. Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Kedrion S.P.A. Recombinant Coagulation Factors Product Portfolio Table 69. Kedrion S.P.A. Recent Development Table 70. Grifols International SA Company Information Table 71. Grifols International SA Business Overview Table 72. Grifols International SA Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Grifols International SA Recombinant Coagulation Factors Product Portfolio Table 74. Grifols International SA Recent Development Table 75. CSL Ltd. Company Information Table 76. CSL Ltd. Business Overview Table 77. CSL Ltd. Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. CSL Ltd. Recombinant Coagulation Factors Product Portfolio Table 79. CSL Ltd. Recent Development Table 80. Biogen Idec Company Information Table 81. Biogen Idec Business Overview Table 82. Biogen Idec Recombinant Coagulation Factors Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Biogen Idec Recombinant Coagulation Factors Product Portfolio Table 84. Biogen Idec Recent Development Table 85. Research Programs/Design for This Report Table 86. Authors List of This Report Table 87. Secondary Sources Table 88. Primary Sources List of Figures Figure 1. Recombinant Coagulation Factors Product Image Figure 2. Global Recombinant Coagulation Factors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Coagulation Factors Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Coagulation Factors Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Recombinant Factor VIII Image Figure 8. Recombinant Factor IX Image Figure 9. Von Willebrand Factor Image Figure 10. Global Recombinant Coagulation Factors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Recombinant Coagulation Factors Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Recombinant Coagulation Factors Sales Value Share by Type (2021-2032) Figure 13. Clinics Image Figure 14. Hospitals Image Figure 15. Research Organizations Image Figure 16. Global Recombinant Coagulation Factors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Recombinant Coagulation Factors Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Recombinant Coagulation Factors Sales Value Share by Application (2021-2032) Figure 19. Global Recombinant Coagulation Factors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Recombinant Coagulation Factors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Recombinant Coagulation Factors Sales Value (2021-2032) & (US$ Million) Figure 22. North America Recombinant Coagulation Factors Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Recombinant Coagulation Factors Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Recombinant Coagulation Factors Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Recombinant Coagulation Factors Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Recombinant Coagulation Factors Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Recombinant Coagulation Factors Sales Value (2021-2032) & (US$ Million) Figure 28. South America Recombinant Coagulation Factors Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Recombinant Coagulation Factors Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Recombinant Coagulation Factors Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Factor VIII
  • Recombinant Factor IX
  • Von Willebrand Factor
Applications
  • Clinics
  • Hospitals
  • Research Organizations
Companies covered
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Bayer AG
  • Baxter International Inc.
  • Octapharma AG
  • Kedrion S.P.A.
  • Grifols International SA
  • CSL Ltd.
  • Biogen Idec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Coagulation Factors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Coagulation Factors Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Recombinant Coagulation Factors Market Dynamics
  1. 2.1 Recombinant Coagulation Factors Industry Trends
  2. 2.2 Recombinant Coagulation Factors Industry Drivers
  3. 2.3 Recombinant Coagulation Factors Industry Opportunities and Challenges
  4. 2.4 Recombinant Coagulation Factors Industry Restraints
3 Recombinant Coagulation Factors Market by Company
  1. 3.1 Global Recombinant Coagulation Factors Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Coagulation Factors Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Coagulation Factors Company Ranking (2024-2026)
  4. 3.4 Global Recombinant Coagulation Factors Company Manufacturing Base and Headquarters
  5. 3.5 Global Recombinant Coagulation Factors Company Product Type and Application
  6. 3.6 Global Recombinant Coagulation Factors Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Recombinant Coagulation Factors Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Recombinant Coagulation Factors Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Recombinant Coagulation Factors Market by Type
  1. 4.1 Recombinant Coagulation Factors Type Introduction
  2. 4.1.1 Recombinant Factor VIII
  3. 4.1.2 Recombinant Factor IX
  4. 4.1.3 Von Willebrand Factor
  5. 4.2 Global Recombinant Coagulation Factors Sales Value by Type
  6. 4.2.1 Global Recombinant Coagulation Factors Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Recombinant Coagulation Factors Sales Value by Type (2021-2032)
  8. 4.2.3 Global Recombinant Coagulation Factors Sales Value Share by Type (2021-2032)
5 Recombinant Coagulation Factors Market by Application
  1. 5.1 Recombinant Coagulation Factors Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Research Organizations
  5. 5.2 Global Recombinant Coagulation Factors Sales Value by Application
  6. 5.2.1 Global Recombinant Coagulation Factors Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Recombinant Coagulation Factors Sales Value by Application (2021-2032)
  8. 5.2.3 Global Recombinant Coagulation Factors Sales Value Share by Application (2021-2032)
6 Recombinant Coagulation Factors Regional Value Analysis
  1. 6.1 Global Recombinant Coagulation Factors Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Coagulation Factors Sales Value by Region (2021-2032)
  3. 6.2.1 Global Recombinant Coagulation Factors Sales Value by Region: 2021-2026
  4. 6.2.2 Global Recombinant Coagulation Factors Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Coagulation Factors Sales Value (2021-2032)
  7. 6.3.2 North America Recombinant Coagulation Factors Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Recombinant Coagulation Factors Sales Value (2021-2032)
  10. 6.4.2 Europe Recombinant Coagulation Factors Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Recombinant Coagulation Factors Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Recombinant Coagulation Factors Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Recombinant Coagulation Factors Sales Value (2021-2032)
  16. 6.6.2 South America Recombinant Coagulation Factors Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Recombinant Coagulation Factors Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Recombinant Coagulation Factors Sales Value Share by Country, 2025 VS 2032
7 Recombinant Coagulation Factors Country-level Value Analysis
  1. 7.1 Global Recombinant Coagulation Factors Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Coagulation Factors Sales Value by Country (2021-2032)
  3. 7.2.1 Global Recombinant Coagulation Factors Sales Value by Country (2021-2026)
  4. 7.2.2 Global Recombinant Coagulation Factors Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Recombinant Coagulation Factors Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Recombinant Coagulation Factors Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Recombinant Coagulation Factors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk A/S
  2. 8.1.1 Novo Nordisk A/S Company Information
  3. 8.1.2 Novo Nordisk A/S Business Overview
  4. 8.1.3 Novo Nordisk A/S Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk A/S Recombinant Coagulation Factors Product Portfolio
  6. 8.1.5 Novo Nordisk A/S Recent Developments
  7. 8.2 Pfizer Inc.
  8. 8.2.1 Pfizer Inc. Company Information
  9. 8.2.2 Pfizer Inc. Business Overview
  10. 8.2.3 Pfizer Inc. Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc. Recombinant Coagulation Factors Product Portfolio
  12. 8.2.5 Pfizer Inc. Recent Developments
  13. 8.3 Bayer AG
  14. 8.3.1 Bayer AG Company Information
  15. 8.3.2 Bayer AG Business Overview
  16. 8.3.3 Bayer AG Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer AG Recombinant Coagulation Factors Product Portfolio
  18. 8.3.5 Bayer AG Recent Developments
  19. 8.4 Baxter International Inc.
  20. 8.4.1 Baxter International Inc. Company Information
  21. 8.4.2 Baxter International Inc. Business Overview
  22. 8.4.3 Baxter International Inc. Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Baxter International Inc. Recombinant Coagulation Factors Product Portfolio
  24. 8.4.5 Baxter International Inc. Recent Developments
  25. 8.5 Octapharma AG
  26. 8.5.1 Octapharma AG Company Information
  27. 8.5.2 Octapharma AG Business Overview
  28. 8.5.3 Octapharma AG Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Octapharma AG Recombinant Coagulation Factors Product Portfolio
  30. 8.5.5 Octapharma AG Recent Developments
  31. 8.6 Kedrion S.P.A.
  32. 8.6.1 Kedrion S.P.A. Company Information
  33. 8.6.2 Kedrion S.P.A. Business Overview
  34. 8.6.3 Kedrion S.P.A. Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kedrion S.P.A. Recombinant Coagulation Factors Product Portfolio
  36. 8.6.5 Kedrion S.P.A. Recent Developments
  37. 8.7 Grifols International SA
  38. 8.7.1 Grifols International SA Company Information
  39. 8.7.2 Grifols International SA Business Overview
  40. 8.7.3 Grifols International SA Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Grifols International SA Recombinant Coagulation Factors Product Portfolio
  42. 8.7.5 Grifols International SA Recent Developments
  43. 8.8 CSL Ltd.
  44. 8.8.1 CSL Ltd. Company Information
  45. 8.8.2 CSL Ltd. Business Overview
  46. 8.8.3 CSL Ltd. Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CSL Ltd. Recombinant Coagulation Factors Product Portfolio
  48. 8.8.5 CSL Ltd. Recent Developments
  49. 8.9 Biogen Idec
  50. 8.9.1 Biogen Idec Company Information
  51. 8.9.2 Biogen Idec Business Overview
  52. 8.9.3 Biogen Idec Recombinant Coagulation Factors Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Biogen Idec Recombinant Coagulation Factors Product Portfolio
  54. 8.9.5 Biogen Idec Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst